Functional Distinctions between IMP Dehydrogenase Genes in Providing Mycophenolate Resistance and Guanine Prototrophy to Yeast*

IMP dehydrogenase (IMPDH) catalyzes the rate-limiting step in the de novo synthesis of GTP. Yeast with mutations in the transcription elongation machinery are sensitive to inhibitors of this enzyme such as 6-azauracil and mycophenolic acid, at least partly because of their inability to transcriptionally induce IMPDH. To understand the molecular basis of this drug-sensitive phenotype, we have dissected the expression and function of a four-gene family in yeast called IMD1 through IMD4. We show here that these family members are distinct, despite a high degree of amino acid identity between the proteins they encode. Extrachromosomal copies of IMD1, IMD3, or IMD4 could not rescue the drug-sensitive phenotype of IMD2 deletants. When overexpressed, IMD3 or IMD4 weakly compensated for deletion of IMD2. IMD1 is transcriptionally silent and bears critical amino acid substitutions compared with IMD2 that destroy its function, offering strong evidence that it is a pseudogene. The simultaneous deletion of all four IMD genes was lethal unless growth media were supplemented with guanine. This suggests that there are no other essential functions of the IMPDH homologs aside from IMP dehydrogenase activity. Although neither IMD3 nor IMD4 could confer drug resistance to cells lacking IMD2, either alone was sufficient to confer guanine prototrophy. The special function of IMD2 was provided by its ability to be transcriptionally induced and the probable intrinsic drug resistance of its enzymatic activity.

[1]  B. Daignan-Fornier,et al.  The isolation and characterization of Saccharomyces cerevisiae mutants that constitutively express purine biosynthetic genes. , 1997, Genetics.

[2]  F. Lacroute,et al.  6-Azauracil inhibition of GTP biosynthesis in Saccharomyces cerevisiae , 1992, Current Genetics.

[3]  J. Hegemann,et al.  Systematic analysis of S. cerevisiae chromosome VIII genes , 1999, Yeast.

[4]  S. Squazzo,et al.  The Paf1 complex physically and functionally associates with transcription elongation factors in vivo , 2002, The EMBO journal.

[5]  R. Schiestl,et al.  Improved method for high efficiency transformation of intact yeast cells. , 1992, Nucleic acids research.

[6]  J. Archambault,et al.  Genetic interaction between transcription elongation factor TFIIS and RNA polymerase II , 1992, Molecular and cellular biology.

[7]  F. B. Pickett,et al.  Splitting pairs: the diverging fates of duplicated genes , 2002, Nature Reviews Genetics.

[8]  Randal J. Shaw,et al.  Saccharomyces cerevisiae Transcription Elongation Mutants Are Defective in PUR5 Induction in Response to Nucleotide Depletion , 2000, Molecular and Cellular Biology.

[9]  F. Collart,et al.  Regulation of IMP dehydrogenase gene expression by its end products, guanine nucleotides , 1991, Molecular and cellular biology.

[10]  A. Kennan,et al.  Identification of an IMPDH1 mutation in autosomal dominant retinitis pigmentosa (RP10) revealed following comparative microarray analysis of transcripts derived from retinas of wild-type and Rho(-/-) mice. , 2002, Human molecular genetics.

[11]  A. Nakano,et al.  Purification, gene cloning, and gene disruption of the transcription elongation factor S-II in Saccharomyces cerevisiae. , 1992, The Journal of biological chemistry.

[12]  R. Jackson,et al.  IMP dehydrogenase, an enzyme linked with proliferation and malignancy , 1975, Nature.

[13]  L. Hedstrom,et al.  IMP dehydrogenase: mechanism of action and inhibition. , 1999, Current medicinal chemistry.

[14]  Seth Blackshaw,et al.  Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. , 2002, Human molecular genetics.

[15]  H. Bussey,et al.  Molecular Cloning of Chromosome I DNA from Saccharomyces cerevisiae: Characterization of the 54 kb Right Terminal CDC15‐FLO1‐PHO11 Region , 1997, Yeast.

[16]  B. Daignan-Fornier,et al.  Transcriptional Regulation of the Yeast GMP Synthesis Pathway by Its End Products* , 2001, The Journal of Biological Chemistry.

[17]  A. Joachimiak,et al.  Differential signatures of bacterial and mammalian IMP dehydrogenase enzymes. , 1999, Current medicinal chemistry.

[18]  Karen T. Smith,et al.  Regulation of an IMP Dehydrogenase Gene and Its Overexpression in Drug-sensitive Transcription Elongation Mutants of Yeast* , 2001, The Journal of Biological Chemistry.

[19]  Milton W. Taylor,et al.  Purine and Pyrimidine Metabolism in Man VIII , 1994, Advances in Experimental Medicine and Biology.

[20]  T. Kodadek,et al.  The 19S regulatory particle of the proteasome is required for efficient transcription elongation by RNA polymerase II. , 2001, Molecular cell.

[21]  P. Lio’,et al.  Analysing gene function after duplication. , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.

[22]  J. Hubert,et al.  Complete sequence of a eukaryotic regulatory gene. , 1983, The EMBO journal.

[23]  B. Daignan-Fornier,et al.  Proteome Analysis and Morphological Studies Reveal Multiple Effects of the Immunosuppressive Drug Mycophenolic Acid Specifically Resulting from Guanylic Nucleotide Depletion* , 2001, The Journal of Biological Chemistry.

[24]  L. Hedstrom,et al.  The roles of conserved carboxylate residues in IMP dehydrogenase and identification of a transition state analog. , 1997, Biochemistry.

[25]  L. Prakash,et al.  Requirement of Yeast RAD2, a Homolog of Human XPG Gene, for Efficient RNA Polymerase II Transcription Implications for Cockayne Syndrome , 2002, Cell.

[26]  G. Weber,et al.  Proliferation-linked regulation of type II IMP dehydrogenase gene in human normal lymphocytes and HL-60 leukemic cells. , 1992, Cancer research.

[27]  Ronald W. Davis,et al.  Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. , 1999, Science.

[28]  B. Mitchell,et al.  Regulation of the Human Inosine Monophosphate Dehydrogenase Type I Gene , 1997, The Journal of Biological Chemistry.

[29]  D. Reines,et al.  Transcription elongation factor SII , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[30]  B. Mitchell,et al.  Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene. , 2000, The Journal of clinical investigation.

[31]  B. Daignan-Fornier,et al.  Screening the Yeast “Disruptome” for Mutants Affecting Resistance to the Immunosuppressive Drug, Mycophenolic Acid* , 2002, The Journal of Biological Chemistry.

[32]  Ronald W. Davis,et al.  Functional profiling of the Saccharomyces cerevisiae genome , 2002, Nature.

[33]  W. Tham,et al.  Transcriptional silencing at Saccharomyces telomeres: implications for other organisms , 2002, Oncogene.

[34]  Ellson Y. Chen,et al.  Overview of manual and automated DNA sequencing by the dideoxy chain termination method , 1991 .

[35]  Mark Gerstein,et al.  A small reservoir of disabled ORFs in the yeast genome and its implications for the dynamics of proteome evolution. , 2002, Journal of molecular biology.

[36]  Mark A. Murcko,et al.  Structure and Mechanism of Inosine Monophosphate Dehydrogenase in Complex with the Immunosuppressant Mycophenolic Acid , 1996, Cell.

[37]  K. H. Wolfe,et al.  Molecular evidence for an ancient duplication of the entire yeast genome , 1997, Nature.